Table_1_Validation of the CRAVE-C scale in Chinese adults: a four-study examination of competing motivations for physical activity versus rest.docx by Zhihui Cheng (296359)

“…In Study 3, higher cardiorespiratory fitness was associated with a slight increase in “Move” desire (3.26% ± 37.35%) and a decrease in “Rest” desire (18.94% ± 66.99%). Lower fitness was linked to a significant decline in “Move” desire (−54.61% ± 111.33%) and an increase in “Rest” desire (43.62% ± 63.64%). …”

Table 1_Assessing and projecting the global impacts of Alzheimer’s disease.docx by Nanlong Zhang (20563511)

“…</p>Conclusion<p>From 1990 to 2030, global burden of AD is projected to decrease, with significant gender and regional disparities. …”

Data Sheet 1_Epidemiological trends and age-period-cohort effects on subarachnoid hemorrhage burden across the BRICS-plus from 1992 to 2021.docx by Liang Guo (95092)

“…Indonesia reported the highest age-standardized incidence rate (10.94 per 100,000 population) in 2021, while China displayed the most significant decrease, at 59.36%. The annual net drift in the SAH incidence rate ranged from −3.36%% for China to −0.50% for the Russian Federation among the eleven countries. …”

The effect of maternal and gestational age on telomere content. by Zuzana Holesova (15253816)

“…<p>A very slight decrease in telomere content with increasing maternal age, but the association is not statistically significant (Pearson’s r = −0.015, p = 0.278) <b>(A)</b>. …”

Table 1_Trends and forecasts of vitamin A deficiency burden in China, 1990–2035.docx by Zhongming Ye (21865547)

“…</p>Results<p>From 1990 to 2021, VAD incidence and prevalence significantly declined across all age groups in China, most notably in children under 5 years (−6.23% average annual change). …”

Data Sheet 1_Characterization of vaginal microbiota across female reproductive phases.zip by Qingzhi Zhai (21265412)

“…</p>Results<p>Microbial communities show significant variations across the different reproductive phases. …”

Image 2_Long-term trends and comparison of the burden of lower respiratory tract infections in China and globally from 1990 to 2021: an analysis based on the Global Burden of Disea... by Zhiwei Wang (120259)

“…Compared with the previous period, the COVID-19 pandemic has led to a significant decrease in the disease burden of LRIs. …”

Table 1_Long-term trends and comparison of the burden of lower respiratory tract infections in China and globally from 1990 to 2021: an analysis based on the Global Burden of Disea... by Zhiwei Wang (120259)

“…Compared with the previous period, the COVID-19 pandemic has led to a significant decrease in the disease burden of LRIs. …”

Image 1_Long-term trends and comparison of the burden of lower respiratory tract infections in China and globally from 1990 to 2021: an analysis based on the Global Burden of Disea... by Zhiwei Wang (120259)

“…Compared with the previous period, the COVID-19 pandemic has led to a significant decrease in the disease burden of LRIs. …”

Table 2_Long-term trends and comparison of the burden of lower respiratory tract infections in China and globally from 1990 to 2021: an analysis based on the Global Burden of Disea... by Zhiwei Wang (120259)

“…Compared with the previous period, the COVID-19 pandemic has led to a significant decrease in the disease burden of LRIs. …”

Supplementary Material for: Long-term trends in incidence, attack rates, and early case-fatality of spontaneous intracerebral hemorrhage. Dijon Stroke Registry (1985-2022) by figshare admin karger (2628495)

“…In men, a significant increase in incidence and attack rates was observed from 1985-1991 to 2011-2016, followed by a slight decline. …”

Image1_Kidney outcomes associated with SGLT2 inhibitors compared to other glucose-lowering drugs: a real-world study from China.TIF by Xiang Xiao (44417)

“…Throughout the follow-up period, we observed a significant decrease in the rate of eGFR decline in patients using SGLT2i (4.94 mL/min/1.73 m² per year reduction compared to oGLDs, 95% CI: 4.73–5.15). …”

Image2_Kidney outcomes associated with SGLT2 inhibitors compared to other glucose-lowering drugs: a real-world study from China.TIF by Xiang Xiao (44417)

“…Throughout the follow-up period, we observed a significant decrease in the rate of eGFR decline in patients using SGLT2i (4.94 mL/min/1.73 m² per year reduction compared to oGLDs, 95% CI: 4.73–5.15). …”

Image8_Kidney outcomes associated with SGLT2 inhibitors compared to other glucose-lowering drugs: a real-world study from China.TIF by Xiang Xiao (44417)

“…Throughout the follow-up period, we observed a significant decrease in the rate of eGFR decline in patients using SGLT2i (4.94 mL/min/1.73 m² per year reduction compared to oGLDs, 95% CI: 4.73–5.15). …”

Image5_Kidney outcomes associated with SGLT2 inhibitors compared to other glucose-lowering drugs: a real-world study from China.TIF by Xiang Xiao (44417)

“…Throughout the follow-up period, we observed a significant decrease in the rate of eGFR decline in patients using SGLT2i (4.94 mL/min/1.73 m² per year reduction compared to oGLDs, 95% CI: 4.73–5.15). …”

Image6_Kidney outcomes associated with SGLT2 inhibitors compared to other glucose-lowering drugs: a real-world study from China.TIF by Xiang Xiao (44417)

“…Throughout the follow-up period, we observed a significant decrease in the rate of eGFR decline in patients using SGLT2i (4.94 mL/min/1.73 m² per year reduction compared to oGLDs, 95% CI: 4.73–5.15). …”

Image3_Kidney outcomes associated with SGLT2 inhibitors compared to other glucose-lowering drugs: a real-world study from China.TIF by Xiang Xiao (44417)

“…Throughout the follow-up period, we observed a significant decrease in the rate of eGFR decline in patients using SGLT2i (4.94 mL/min/1.73 m² per year reduction compared to oGLDs, 95% CI: 4.73–5.15). …”

DataSheet1_Kidney outcomes associated with SGLT2 inhibitors compared to other glucose-lowering drugs: a real-world study from China.pdf by Xiang Xiao (44417)

“…Throughout the follow-up period, we observed a significant decrease in the rate of eGFR decline in patients using SGLT2i (4.94 mL/min/1.73 m² per year reduction compared to oGLDs, 95% CI: 4.73–5.15). …”

Image4_Kidney outcomes associated with SGLT2 inhibitors compared to other glucose-lowering drugs: a real-world study from China.TIF by Xiang Xiao (44417)

“…Throughout the follow-up period, we observed a significant decrease in the rate of eGFR decline in patients using SGLT2i (4.94 mL/min/1.73 m² per year reduction compared to oGLDs, 95% CI: 4.73–5.15). …”

Image7_Kidney outcomes associated with SGLT2 inhibitors compared to other glucose-lowering drugs: a real-world study from China.TIF by Xiang Xiao (44417)

“…Throughout the follow-up period, we observed a significant decrease in the rate of eGFR decline in patients using SGLT2i (4.94 mL/min/1.73 m² per year reduction compared to oGLDs, 95% CI: 4.73–5.15). …”